Nifekalant and disopyramide in a patient with short QT syndrome: Evaluation of pharmacological effects and electrophysiological properties

PACE - Pacing and Clinical Electrophysiology

Volumn 31, Issue 9, 2008, Pages 1229-1232

  Mizobuchi, Masahiro ^a   Enjoji, Yoshihisa ^a   Yamamoto, Ryuji ^a   Ono, Tsuyoshi ^a   Funatsu, Atsushi ^a   Kambayashi, Daisuke ^a   Kobayashi, Tomoko ^a   Nakamura, Shigeru ^a  

^a KYOTO KATSURA HOSPITAL   (Japan)

Author keywords

Disopyramide; HR QT relationship; Nifekalant; Short QT syndrome

Indexed keywords

DISOPYRAMIDE; NIFEKALANT;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; DEFIBRILLATOR; ELECTROCARDIOGRAM; HEART RATE VARIABILITY; HEART RIGHT ATRIUM; HUMAN; IMPLANTATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; QT INTERVAL; SHORT QT SYNDROME; SUDDEN DEATH; T WAVE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BODY SURFACE POTENTIAL MAPPING; DISOPYRAMIDE; HUMANS; MALE; PYRIMIDINONES; SYNDROME; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 50449105981     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2008.01169.x     Document Type: Article

References (11)

1. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S, et al. Short QT Syndrome: A familial cause of sudden death. Circulation 2003 108 : 965 970.
2. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004 109 : 30 35.
3. Bellocq C, vanGinneken AC, Bezzina CR, Alders M, Escande D, Mannens MM, Baro I, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004 109 : 2394 2397.
4. Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A, Napolitano C, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005 96 : 800 807.
5. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 2005 16 : 394 396.
6. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 2005 16 : 54 58.
7. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: Diagnostic accuracy of the paradoxical QT response. Circulation 2006 113 : 1385 1392.
8. Kushida S, Ogura T, Komuro I, Nakaya H. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: Mode of action. Eur J Pharmacol 2002 457 : 19 27.
9. + channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 2006 41 : 563 566.
10. + channel inhibition by disopyramide in patients with a short QT-1 syndrome: A pilot study. J Cardiovasc Electrophysiol 2007 (in press).
11. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calo L, Brugada R, et al. Short QT syndrome: Pharmacological treatment. J Am Coll Cardiol 2004 43 : 1494 1499.